Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | UGCG | Q16739 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21020176 | 0.97 | HDAC1 (0.46) | HDAC1HDAC6ACACBPRMT5WDR77 | |
| SCHEMBL21020197 | 0.90 | ACACB (0.44) | ACACBPRMT5WDR77 | |
| SCHEMBL21021808 | 0.87 | ACACB (0.46) | ACACBPRMT5WDR77LMNASMN1; SMN2 | |
| SCHEMBL21020880 | 0.87 | ACACB (0.38) | HDAC1ACACB | |
| SCHEMBL21020174 | 0.86 | MAPT (0.38) | HDAC1HDAC6PRMT5WDR77LMNA | |
| SCHEMBL24063578 | 0.85 | ACACB (0.54) | HDAC1HDAC6ACACBPRMT5WDR77 | |
| SCHEMBL21020779 | 0.84 | ACACB (0.40) | ACACB | |
| SCHEMBL21020889 | 0.84 | MEN1 (0.39) | HDAC1HDAC6PRMT5WDR77LMNA | |
| SCHEMBL21020840 | 0.84 | MEN1 (0.37) | HDAC1HDAC6ACACBPRMT5WDR77 | |
| SCHEMBL21020899 | 0.84 | PSMB5 (0.40) | HDAC1HDAC6PRMT5WDR77DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186548-B2 | Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | U.S. DEPARTMENT OF ENERGY | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | ACHE, BCHE, CHAT | HDAC1 230/4885HDAC6 1134/4885ACACB 178/4885 |
| US-11186548-B2 | Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them | ACHE, BCHE, CHAT | HDAC1 230/4885HDAC6 1134/4885ACACB 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.